Mark Yore News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Jounce Therapeutics Announces Pricing of $56.25 Million Public Offering of Common Stock CAMBRIDGE, Mass., March 09, 2021 (GLOBE NEWSWIRE) — Jounce Therapeutics, Inc. (Nasdaq: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it has priced an underwritten public offering of 5,000,000 shares of common stock at a public offering price of $11.25 per share, which would result in gross proceeds of approximately $56.25 million, before underwriting discounts and commissions. The proceeds of the of...

Jounce Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results – Commenced enrollment in both the Phase 1 INNATE trial of JTX-8064 (LILRB2 / ILT4) and the Phase 2 SELECT trial of Vopratelimab in combination with JTX-4014 – – Ended 2020 with $213.2 million in cash, cash equivalents and investments – – Company to host conference call and webcast today at 8:00 AM ET – CAMBRIDGE, Mass., Feb. 25, 2021 (GLOBE NEWSWIRE) — Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predi...